Hans Moebius

Chief Tech/Sci/R&D Officer at Exciva GmbH

Net worth: 175 645 $ as of 30/04/2024

68 year

33 connections

Health Technology

Consumer Services

Commercial Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Mark Litton	M	56	ATHIRA PHARMA, INC.	5 years
Kelly Romano	F	62	ATHIRA PHARMA, INC.	4 years
Grant Pickering	M	56	ATHIRA PHARMA, INC.	2 years
Joseph Edelman	M	67	ATHIRA PHARMA, INC.	4 years
James Johnson	M	67	ATHIRA PHARMA, INC.	4 years
Barbara Kosacz	F	66	ATHIRA PHARMA, INC.	3 years
Mark Worthington	M	58	ATHIRA PHARMA, INC.	3 years
Michael Panzara	M	57	ATHIRA PHARMA, INC.	2 years
Robert Renninger	M	-	ATHIRA PHARMA, INC.	4 years
Rachel Lenington	F	51	ATHIRA PHARMA, INC.	3 years
Andrew Gengos	M	59	ATHIRA PHARMA, INC.	1 years
François Conquet	M	-	Exciva GmbH Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet.	-
Bespalov Anton	M	-	Exciva GmbH Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet.	-

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Leen Kawas	M	38	ATHIRA PHARMA, INC.	10 years
Tadataka Yamada	M	77	ATHIRA PHARMA, INC.	2 years
Glenna Mileson	F	66	ATHIRA PHARMA, INC.	8 years
George Bickerstaff	M	68	ATHIRA PHARMA, INC.	-
Josh Pan	M	-	ATHIRA PHARMA, INC.	7 years
Xue Hua	M	-	ATHIRA PHARMA, INC.	7 years
Samantha Haeberlein	M	-	Rodin Therapeutics, Inc. Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA.	-
Setsuko Hashimoto	M	70	Ruprecht-Karls-Universität Heidelberg	3 years
Helmut Kraft	M	64	Ruprecht-Karls-Universität Heidelberg	5 years
Norbert Steiner	M	70	Ruprecht-Karls-Universität Heidelberg	3 years
Bernd Eisele	M	-	Ruprecht-Karls-Universität Heidelberg	3 years
Roland Kaplan	M	-	Ruprecht-Karls-Universität Heidelberg	4 years
Klaus Dembowsky	M	-	Ruprecht-Karls-Universität Heidelberg	3 years
Bernhard R. M. Ehmer	M	69	Ruprecht-Karls-Universität Heidelberg	6 years
Utz-Hellmuth Felcht	M	76	Technische Universität Kaiserslautern	3 years
Peter Gruss	M	74	Ruprecht-Karls-Universität Heidelberg	4 years
Luis Miguel Cardozo Goytizolo	M	73	Ruprecht-Karls-Universität Heidelberg	3 years
Joachim Müller	M	65	Ruprecht-Karls-Universität Heidelberg	4 years
Richard Kayne	M	79	ATHIRA PHARMA, INC.	-
Lawrence E. Chun	M	-	ATHIRA PHARMA, INC.	7 years

Statistics

Country	Connections	% of total
United States	20	60.61%
Germany	13	39.39%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections